The Medical Letter on Drugs and Therapeutics
Low-Dose Meloxicam (Vivlodex) for Osteoarthritis Pain
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Vivlodex (Iroko), a low-dose formulation of the nonsteroidal anti-inflammatory drug meloxicam (Mobic, and generics), for management of osteoarthritis pain. According to the manufacturer, the new formulation aligns with stronger FDA warnings about the cardiovascular risks of NSAIDs and the recommendation to use the lowest possible doses of these drugs.1

STANDARD TREATMENT — Acetaminophen is generally the first-line pharmacologic treatment for osteoarthritis pain. Full doses of NSAIDs are more effective than full doses of acetaminophen, but NSAIDs have many more adverse effects, especially in elderly patients. Intra-articular injection of a corticosteroid is a reasonable alternative. Opioids can be used as a last resort for treatment of intractable osteoarthritis pain.2

THE NEW ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Low-Dose Meloxicam (Vivlodex) for Osteoarthritis Pain
Article code: 1490c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian